Enrollment Approximately 50 Percent Complete in Cellceutix

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis

BEVERLY, MA --(Marketwired - September 30, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today announces that the Company's Phase 2 clinical trial of the oral drug candidate Prurisol for psoriasis has now enrolled approximately 50 percent of the planned number of patients. The trial was designed to enroll 100 patients with active mild to moderate chronic plaque psoriasis. Enrollment is expected to be completed by the end of 2015.

The randomized, double-blind study consists of four arms, with the three active arms receiving different dosing levels of oral Prurisol daily and the fourth arm receiving only placebo daily. The primary efficacy endpoint will be the percentage of subjects with ≥ 2 point improvement in Investigator's Global Assessment (IGA) rating as defined by visual inspections of psoriasis lesions over a period of up to 84 days. More information on the trial is available on the clinicaltrials.gov website at: https://clinicaltrials.gov/ct2/show/NCT024944...tix&rank=1 .

There is an unmet medical need for an effective oral treatment for plaque psoriasis as an alternative to biologic therapies, which currently dominate the market. Cellceutix is very pleased with the steady pace of enrollment in the eight weeks since the trial commenced. To date, no serious adverse events have been reported.

Separately, Cellceutix would like to inform shareholders that approximately 30 pounds of the active pharmaceutical ingredient (API) in Brilacidin has been manufactured. The API will soon begin formulation for use in the planned clinical trials of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and other indications.

Alerts: Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs

Cellceutix clinical trials on Clinicaltrials.gov: https://clinicaltrials.gov/ct2/results?term=c...rch=Search

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 39

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Market Sentiment: Is APA Corp in a Bullish Phase?

Updated Category News Views 154

Understanding APA Corp's Short Interest Dynamics APA Corp's (NYSE: APA) stock has been under the microscope recently as its short interest, a key indicator for traders, has experienced a notable decline of 13.7%. This brings the total number of shares sold short to approximately 33.81 million, representing about 10.77% of all shares available for trading. Based on the...

Continue Reading
Market Insights: Oil Prices Rise While BioVie Shares Drop

Updated Category News Views 113

Market Overview In recent trading sessions, U.S. stocks showed varied performances. While the Dow Jones index experienced a slight drop, other indices like NASDAQ and S&P 500 managed to post modest gains. Stock Performance The Dow Jones fell by 0.04%, closing at 42,109.03. In contrast, the NASDAQ increased by 0.51%, finishing at 18,065.98, and the S&P 500 also climbed by...

Continue Reading
NTG Nordic Transport Group Adjusts Shareholding Structure

Updated Category News Views 242

NTG Nordic Transport Group Announces Shareholding Reduction In an important announcement, NTG Nordic Transport Group A/S (“NTG”) has updated its shareholders regarding its treasury shares following a strategic acquisition. The company reported that as of January 10, 2025, it owns 954,723 treasury shares, equivalent to a nominal value of DKK 20 each, totaling to a...

Continue Reading
Understanding Sydbank A/S Buyback Initiatives and Trends

Updated Category News Views 217

Insights into Sydbank A/S Share Buyback Program Welcome to an exploration of the recent developments surrounding the share buyback program initiated by Sydbank A/S. This financial strategy serves as a key indicator of the health and direction of the company. What is the Share Buyback Program? Recently, Sydbank A/S rolled out a share buyback initiative set at DKK 1,350...

Continue Reading
Governor Whitmer's Initiative to Enhance Education for Young Men

Updated Category News Views 129

Governor Whitmer Enhances Educational Opportunities for Young Men In a significant move aimed at supporting young men's access to education, Governor Gretchen Whitmer of Michigan has announced an executive directive that focuses on skills training and higher education enrollment. This initiative underscores the state’s commitment to educational and economic...

Continue Reading